[Translation] A randomized, blinded, non-inferiority phase III clinical trial to evaluate the immunogenicity and safety of quadrivalent influenza virus split vaccine in people aged 3 years and above
采用随机、盲法、非劣效Ⅲ期临床试验方法,评价大连雅立峰生物制药有限公司四价流感病毒裂解疫苗在3岁及以上人群中接种免疫原性和安全性。探索四价流感病毒裂解疫苗在3-8岁人群中于0、28天接种2剂的免疫原性。探索四价流感病毒裂解疫苗在3-8岁既往接种过流感疫苗人群与既往未接种过流感疫苗人群中不同接种程序的免疫原性。
[Translation] A randomized, blinded, non-inferiority phase III clinical trial was conducted to evaluate the immunogenicity and safety of the quadrivalent influenza virus split vaccine developed by Dalian Yalifeng Biopharmaceutical Co., Ltd. in people aged 3 years and above. The immunogenicity of the quadrivalent influenza virus split vaccine was explored in people aged 3-8 years with two doses on days 0 and 28. The immunogenicity of the quadrivalent influenza virus split vaccine was explored in different vaccination schedules in people aged 3-8 years who had received influenza vaccine before and those who had not received influenza vaccine before.